Cargando…
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340488/ https://www.ncbi.nlm.nih.gov/pubmed/35923762 http://dx.doi.org/10.1002/mco2.154 |
_version_ | 1784760416167002112 |
---|---|
author | Jiang, Yujie Zhao, Tingmei Zhou, Xueyan Xiang, Yu Gutierrez‐Castrellon, Pedro Ma, Xuelei |
author_facet | Jiang, Yujie Zhao, Tingmei Zhou, Xueyan Xiang, Yu Gutierrez‐Castrellon, Pedro Ma, Xuelei |
author_sort | Jiang, Yujie |
collection | PubMed |
description | The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19. |
format | Online Article Text |
id | pubmed-9340488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93404882022-08-02 Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions Jiang, Yujie Zhao, Tingmei Zhou, Xueyan Xiang, Yu Gutierrez‐Castrellon, Pedro Ma, Xuelei MedComm (2020) Reviews The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19. John Wiley and Sons Inc. 2022-08-01 /pmc/articles/PMC9340488/ /pubmed/35923762 http://dx.doi.org/10.1002/mco2.154 Text en © 2022 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Jiang, Yujie Zhao, Tingmei Zhou, Xueyan Xiang, Yu Gutierrez‐Castrellon, Pedro Ma, Xuelei Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
title | Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
title_full | Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
title_fullStr | Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
title_full_unstemmed | Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
title_short | Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
title_sort | inflammatory pathways in covid‐19: mechanism and therapeutic interventions |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340488/ https://www.ncbi.nlm.nih.gov/pubmed/35923762 http://dx.doi.org/10.1002/mco2.154 |
work_keys_str_mv | AT jiangyujie inflammatorypathwaysincovid19mechanismandtherapeuticinterventions AT zhaotingmei inflammatorypathwaysincovid19mechanismandtherapeuticinterventions AT zhouxueyan inflammatorypathwaysincovid19mechanismandtherapeuticinterventions AT xiangyu inflammatorypathwaysincovid19mechanismandtherapeuticinterventions AT gutierrezcastrellonpedro inflammatorypathwaysincovid19mechanismandtherapeuticinterventions AT maxuelei inflammatorypathwaysincovid19mechanismandtherapeuticinterventions |